Lake Street initiated coverage on Nutex Health (NUTX) on June 2, 2026.
The investment bank assigned a "Buy" rating.
It set a price target of $235.00.
The rating suggests significant upside potential from the closing price on the announcement day.
Analyst Ben Haynor cited several factors for the positive outlook.
Haynor noted the micro-hospital operator trades at a low valuation.
Haynor suggested the stock is undervalued.
Reasons include its path to the public market via a reverse merger.
A previous lack of analyst coverage also contributes.
Investors also generally misunderstand the No Surprises Act.